GAFA
AUTL

Garton & Associates Financial Advisors’s Autolus Therapeutics AUTL Stock Holding History

Garton & Associates Financial Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-600
Closed -$1.19K – 163
2025
Q4 		$1.19K Buy
+600
New +$922 ﹤0.01% 1125

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Garton & Associates Financial Advisors's AUTL Position: Q1 2026 in Review

Garton & Associates Financial Advisors sold out of Autolus Therapeutics (AUTL) in Q1 2026, closing a stake of 600 shares — an estimated $1.19K sold.

Garton & Associates Financial Advisors first reported a position in AUTL in Q4 2025 and held it in 1 quarter. The position peaked at $1.19K in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • Garton & Associates Financial Advisors reported no remaining Autolus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Garton & Associates Financial Advisors sold 600 Autolus Therapeutics shares in Q1 2026, an estimated $1.19K.
  • Garton & Associates Financial Advisors first reported a position in Autolus Therapeutics in Q4 2025 and held it in 1 quarter.
  • Garton & Associates Financial Advisors's Autolus Therapeutics position peaked at $1.19K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on Garton & Associates Financial Advisors's 13F filing for Q1 2026, filed 11 May 2026.